Albiglutide (Tanzeum): Research & Studies

Research Overview#

Albiglutide was evaluated in the HARMONY clinical trial program, one of the largest development programs for a GLP-1 receptor agonist. The program comprised eight phase 3 trials (HARMONY 1-8) enrolling over 5,000 patients with type 2 diabetes, plus the HARMONY Outcomes cardiovascular outcomes trial (n=9,463).

The evidence level is classified as high because the clinical data include large, well-designed randomized controlled trials with cardiovascular outcomes data, despite the drug's commercial discontinuation.

HARMONY Outcomes: Cardiovascular Benefit#

The HARMONY Outcomes trial (Hernandez et al., 2018; PMID 30291013) was the defining study of albiglutide's clinical program. This double-blind, randomized, placebo-controlled trial enrolled 9,463 patients with type 2 diabetes and established cardiovascular disease across 610 sites in 28 countries.

Key results:

• Primary endpoint (3-point MACE): HR 0.78 (95% CI 0.68-0.90, P=0.0006)
• 22% relative risk reduction in the composite of cardiovascular death, myocardial infarction, or stroke
• Results were consistent across prespecified subgroups including age, sex, baseline HbA1c, and BMI
• No significant increase in adverse events compared to placebo

The irony of HARMONY Outcomes is that this positive cardiovascular benefit was demonstrated and published in October 2018, more than a year after GSK had already withdrawn albiglutide from the market in July 2017. The result confirmed albiglutide as one of the GLP-1 agonists with proven cardiovascular benefit, alongside liraglutide (LEADER) and semaglutide (SUSTAIN-6, SELECT).

HARMONY Phase 3 Program#

HARMONY 2: Versus Placebo (Diet and Exercise Failure)#

HARMONY 2 (Nauck et al., 2016; PMID 26577795) compared albiglutide 30 mg and 50 mg weekly to placebo in 309 patients inadequately controlled on diet and exercise alone. Both doses demonstrated superior HbA1c reduction at 52 weeks. The GI side effect profile was notably milder than other GLP-1 agonists, with nausea rates of approximately 10-12%.

HARMONY 7: Head-to-Head Versus Liraglutide#

HARMONY 7 was a critical trial that directly compared albiglutide 50 mg weekly to liraglutide 1.8 mg daily. This study revealed albiglutide's key limitation: it was inferior to liraglutide for HbA1c reduction, failing the non-inferiority primary endpoint. This result positioned albiglutide as less effective than a daily GLP-1 agonist, significantly undermining its commercial viability.

Evidence Quality Assessment#

Research Evidence Context#

Albiglutide (Tanzeum) belongs to the Metabolic category of research peptides. The research evidence for Albiglutide (Tanzeum) spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Albiglutide (Tanzeum):

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial#

Authors: Hernandez AF, Green JB, Janmohamed S, et al. (2018) — The Lancet

Landmark cardiovascular outcomes trial (n=9,463) demonstrating that albiglutide reduced major adverse cardiovascular events (MACE) by 22% in patients with type 2 diabetes and established cardiovascular disease. Published after market withdrawal.

Key Findings:

• Primary endpoint (3-point MACE): HR 0.78, 95% CI 0.68-0.90, P=0.0006
• 22% relative risk reduction in cardiovascular death, MI, or stroke
• Median follow-up: 1.6 years
• Results were consistent across prespecified subgroups
• No significant difference in all-cause mortality (HR 0.95, P=0.56)

Limitations: Published after market withdrawal, limiting clinical impact. Shorter follow-up than some other CVOTs (median 1.6 years). Product no longer available, making the positive result purely of scientific interest.

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise#

Authors: Nauck MA, Stewart MW, Perkins C, et al. (2016) — Diabetologia

Phase 3 trial comparing albiglutide 30 mg and 50 mg weekly to placebo in 309 patients with T2D inadequately controlled on diet and exercise. Both doses demonstrated superior glycemic control at 52 weeks.

Key Findings:

• Both albiglutide 30 mg and 50 mg were superior to placebo for HbA1c reduction at 52 weeks
• Modest weight loss observed in albiglutide groups
• GI adverse events were lower than typically seen with other GLP-1 agonists
• Generally well tolerated over 52-week treatment period

Limitations: Placebo-controlled design does not allow direct comparison with active GLP-1 agonist competitors. Relatively small sample size (n=309).

Evidence Quality Assessment#

The overall evidence level for Albiglutide (Tanzeum) is classified as high, supported by large, well-designed clinical trials with robust methodology.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Albiglutide (Tanzeum) have been identified:

• No head-to-head comparison with semaglutide was ever conducted
• Long-term cardiovascular outcome data beyond 1.6 years were not obtained due to market withdrawal
• Whether the HARMONY Outcomes CV benefit was a class effect or specific to albiglutide remains uncertain
• The potential for reformulation to improve reconstitution complexity was never explored commercially

Addressing these research gaps will be important for establishing a more complete understanding of Albiglutide (Tanzeum)'s therapeutic potential and safety profile.

Related Reading#

• Albiglutide (Tanzeum) overview and research guide
• Albiglutide (Tanzeum) dosing protocols
• Albiglutide (Tanzeum) molecular structure